Edition:
United States

Ipsen SA (IPN.PA)

IPN.PA on Paris Stock Exchange

144.10EUR
11:35am EDT
Change (% chg)

€1.55 (+1.09%)
Prev Close
€142.55
Open
€142.50
Day's High
€144.25
Day's Low
€141.80
Volume
71,557
Avg. Vol
92,019
52-wk High
€145.65
52-wk Low
€97.24

Select another date:

Thu, Apr 26 2018

BRIEF-Ipsen Q1 Sales up at 510.3 Million Euros

* IPSEN REPORTS STRONG Q1 2018 SALES GROWTH OF 23.1% AT CONSTANT EXCHANGE RATES

BRIEF-Ipsen Announces EMA Validation Of Filing Of New Application For Additional Indication For Cabometyx®

* ANNOUNCES EMA VALIDATION OF FILING OF A NEW APPLICATION FOR ADDITIONAL INDICATION FOR CABOMETYX®, FOR PATIENTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA (HCC)

BRIEF-Ipsen Receives Positive CHMP Opinion For Cabometyx

* IPSEN RECEIVES POSITIVE CHMP OPINION FOR CABOMETYX® (CABOZANTINIB) FOR THE FIRST-LINE TREATMENT OF ADULTS WITH INTERMEDIATE- OR POOR- RISK ADVANCED RENAL CELL CARCINOMA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Ipsen Announces Health Canada Approval Of Dysport Therapeutic For Treatment Of Lower Limb Spasticity In Adults

* IPSEN ANNOUNCES HEALTH CANADA APPROVAL OF DYSPORT THERAPEUTIC (ABOBOTULINUMTOXINA) FOR THE TREATMENT OF LOWER LIMB SPASTICITY IN ADULTS

Select another date: